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BACKGROUND AND OBJECTIVES
Personalized medicine is the tailoring of therapies to 
defined subsets of patients based on their likelihood to 
respond to therapy or their risk of adverse events. This 
emerging approach holds great promise for improving 
human health and optimizing the development and 
clinical use of medications. New medicines targeting 
discrete molecular subclasses of tumours have been re-
cently approved aiming to treat and monitor patients 
more precisely and effectively and in ways that better 
meet their needs. A new report from the Personalized 
Medicine Coalition shows that in 2016, for the third 
year in a row, personalized medicines accounted for 
more than 20 percent of the new molecular entities 
approved by the US Food and Drug Administration 
(FDA) [1].
Precision medicine – the use of comprehensive ge-
nomic, proteomic or even “pan-omic” characterization 
of patients to guide medical decisions – is a key step 
towards truly personalized medicine, implying the com-
bination of biomarker and molecular information with 
a specific clinical phenotype at the individual patient 
level [2, 3].
This new approach has drawn increasing interest in 
the past few years in the medical and scientific commu-
nities and efforts are underway to promote its develop-
ment. Indeed in 2015 the former President of the Unit-
ed States, Barack Obama, announced the “Precision 
Medicine Initiative”, a research investment plan aim-
ing to accelerate progress towards precision medicine 
(https://obamawhitehouse.archives.gov/node/333101). 
The goal, he said, was “delivering the right treatment 
at the right time, every time, to the right person”. Simi-
larly in the European Union both Europe-wide (e.g. the 
Innovative Medicine Initiative (www.imi.europa.eu/) 
supported by the European Medicines Agency) and 
country-specific projects on precision medicine have 
been successfully developed in the last years [4].
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Abstract
Background. Despite advances in technology development for precision medicine, ob-
stacles remain as barriers to progress and change. In this context simple questions arise: 
what is the level of understanding of precision medicine among healthcare professionals? 
We tried to address this question with a survey whose objective was to explore the per-
ception and understanding of precision medicine. 
Methods. A questionnaire was administered to a sample made of oncologists, clinical 
and hospital pharmacists, pharmacologists and infectiologists in the context of five dif-
ferent Italian national congresses. Participation in the survey was voluntary and anony-
mous. 
Results. The questionnaire was filled-in by a total number of 1113 professionals out of 
3670 registered participants in the congresses. About half of respondents stated they 
were not sufficiently informed about precision medicine, and infectiologists were the 
ones who felt less informed. Most respondents agreed with the basic principles and defi-
nitions of precision medicine and believed this new approach is going to require deep 
changes in healthcare.
Conclusions. Our findings show that healthcare professionals have partial knowledge on 
this topic and that there is a significant association between respondents’ knowledge and 
their clinical specialty. However, despite some misconceptions about precision medicine, 
a genuine interest and familiarity with its basic principles seems to emerge. 
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However, despite the advances in technology devel-
opment and the emerging clinical applications for pre-
cision medicine, significant practical obstacles remain 
as barriers to progress and true change. Contributing 
forces are both cultural and technological: medical 
practice does not easily keep pace with rapid techno-
logical advances and uptake into clinical care will ne-
cessitate a change in culture and perception, whereby 
genomic information is seen as routine for health care 
[5]. Moreover, a simple question arises: what is the level 
of understanding of precision medicine among health 
care professionals? Are there health care professionals 
less or more exposed/informed than others? Are their 
information needs adequately addressed? We tried to 
address these key questions with a survey whose objec-
tive was to explore the perception and understanding 
of precision medicine among health care professionals, 
including other related challenges, such as patients’ ex-
pectations, funding and organizational issues. 
METHODS
This is the first survey conducted within the “For-
ward” project (http://forward.recentiprogressi.it/) in-
volving both public and private stakeholders and col-
lecting the opinions of a number of different health 
care professionals with a dedicated issue on Precision 
Medicine in 2016. A short report of this analysis was 
previously published in Italian on the Forward project 
website (http://forward.recentiprogressi.it/numero-1/i-
risultati-della-survey/). To this purpose, a questionnaire 
was prepared by the Forward working group and ad-
ministered to a sample made of oncologists, clinical and 
hospital pharmacists, pharmacologists; infectiologists 
were also chosen as an additional group of profession-
als since they are expected to be less exposed to preci-
sion medicine than others. The questionnaire consisted 
of 20 questions, organized in 3 sections covering the 
general perception of precision medicine, general con-
cerns on this field, and finally personal and professional 
characteristics of respondents (see Table 2). Participa-
tion in the survey was voluntary and anonymous. Given 
the nature of the study, exclusively based on the admin-
istration of a questionnaire and the collection of anony-
mous data with no disclosure of confidential/sensitive 
information by respondents, formal approval by ethics 
committees was not required. 
The questionnaires were administered in the context 
of five different Italian national congresses. During 
each event, there was an information desk dedicated to 
the Forward project, where the project staff provided 
general information and distributed copies of the ques-
tionnaire. 
The national congresses involved were: 
1. the 17th National Congress of the Italian Association 
of Medical Oncology (AIOM) held in Rome from 23 
to 25 October, 2015; 
2. the 3rd National Congress of the Italian Society of 
Clinical Pharmacy and Therapy (SIFaCT), held in 
Rome from 8 to 10 October, 2015;
3. the 36th National Congress of the Italian Society of 
Hospital Pharmacy (SIFO), held in Catania from 22 
to 25 October, 2015;
4. the 37th National Congress of the Italian Society of 
Pharmacology (SIF), held in Naples from 27 to 30 
October, 2015;
5. the 14th National Congress of the Italian Society of 
Infectious and Tropical Diseases (SIMIT), held in 
Catania from 8 to 11 November 2015.
The reason for choosing these events was that they 
were all major national and consecutive conferences. 
The first step of the study was a descriptive analysis, in-
cluding the calculation of absolute and relative frequen-
cies. The second step consisted of a bivariate analysis 
using the Chi-square test, in order to assess possible 
statistical correlations of the different variables using a 
statistical significance level of 0.05.
RESULTS
The questionnaire was filled-in by a total number of 
1113 professionals out of 3670 registered participants 
in the five congresses (30.3%). 
Characteristics of respondents are summarized in 
Table 1.
The first item of the questionnaire explored to what 
extend respondents felt familiar with the concept of 
precision medicine (Question 1, see Table 2). This al-
lowed a first grouping of respondents based on their an-
swers: 52.6% stated they were not sufficiently informed 
and 40.7% stated they were only partially informed. 
Only 6.7% of respondents considered themselves as ap-
propriately informed on this topic (Figure 1). 
The difference among answers is due to the pres-
ence of a significant association (p < 0.05) between 
the respondents’ degree of information on precision 
medicine and their clinical specialty. Infectiologists (the 
group that appeared to be less inclined to answer to the 
questionnaire) felt they did not know enough on this 
topic, whereas oncologists and pharmacologists felt suf-
ficiently informed. On the other hand, no significant as-
sociations were found between the respondents’ degree 
of information and their age, gender and geographical 
region of work. 
Another question (Question 2, see Table 2) tested 
the level of knowledge on the initiative on precision 
medicine launched by the US Government. Almost 
Table 1
Characteristics of study respondents
Number %
Oncologists 307 28
Clinical/hospital pharmacists 428 38
Pharmacologists 277 25
Infectiologists 101 9
Males 380 34
Females 733 66
Northern Italy 376 34
Central Italy 325 29
Southern Italy 272 24
Islands 149 13
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the totality of respondents (89.8%) ignored that the 
institution launching this investment plan was the 
White House. About 70% (68.8%) of respondents 
admitted they did not know, 15.2% thought the insti-
tution was the World Health Organization, for 2.9% 
it was National Institute for Health and Care Excel-
lence (NICE), while for 3.1% the European Union. 
Only 10.2% gave the right answer. Oncologists were 
the most informed specialists on this initiative, while 
pharmacologists and infectiologists were the ones who 
more frequently attributed the initiative to the World 
Health Organization.
Of note, most of the respondents who felt sufficiently 
informed about precision medicine gave the right an-
swer. 
In this first section of the questionnaire respondents 
were also asked to express their agreement/disagree-
ment (full agreement, partial agreement, partial dis-
agreement, complete disagreement) on a number of 
statements about precision medicine.
Table 2
Complete set of questions and possible answers administered to each respondent 
Question 1. Do you feel informed enough about precision medicine? 
Yes/No/Partially.
Question 2. Which institution has launched an important research investment in precision medicine in January 2015? 
World Health Organization/European Union/The Government of the United States of America/The National Institute for Health and Care 
Excellence/I don’t know.
Question 3. Do you agree with the following statement: “Precision medicine implies health care decision-making tailored on patients 
characteristics”? 
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 4. Do you agree with the following statement: “Precision medicine implies the development of therapies targeting individual 
patients characteristics”? 
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 5. Do you agree with the following statement: “Precision medicine implies the identification of subpopulations with different 
susceptibility to certain diseases and different response to specific therapies”? 
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 6. Do you agree with the following statement: “Precision medicine and personalized/individualized medicine are synonyms”?
I fully agree/I partially agree/I partially disagree/I completely disagree
Question 7. Do you agree with the following statement: “Precision medicine greatly emphasizes the importance of the individual patient. 
This contrasts with the typically difficult relationship between patients and physicians”?
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 8. Do you agree with the following statement: “Precision medicine, shifts the emphasis on disciplines such as molecular biology, or 
immunology. This may potentially distract health care professionals from their core business i.e. curing patients”?
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 9. Do you agree with the following statement: “Precision medicine is an alternative to evidence-based medicine. Indeed focusing 
on the individual patient implies the overcoming of population-medicine”?
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 10. Do you agree with the following statement: “Precision medicine can be successful in treating limited types of diseases with a 
strong genetic component”?
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 11. Do you agree with the following statement: “Resource allocation in precision medicine will subtract resources from sectors 
more strategically important, such as prevention or rehabilitation”?
I fully agree/I partially agree/I partially disagree/I completely disagree.
Question 12. How would you rate the outcomes reached so far in certain therapeutic areas e.g., oncology, through precision medicine?
Very promising/Sufficiently promising/Not sufficiently promising to justify investment/Not promising.
Question 13. Do you think that precision medicine will require changes in the hospital organization?
Certainly yes/Probably yes/Probably no/Certainly no.
Question 14. Do you think that precision medicine will create excessive expectations among patients and their families?
Certainly yes/Probably yes/Probably no/Certainly no.
Question 15. Do you think that precision medicine will require a different training of physicians and pharmacists?
Certainly yes/Probably yes/Probably no/Certainly no
Question 16. Are there additional topics that should have been included, but were not covered in this survey?
Yes (if yes, elaborate which topics you would add)/No/I don’t know.
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Question 3 (see Table 2) explored the level of agree-
ment on precision medicine as an approach imply-
ing health care decision-making tailored on patients 
characteristics. Almost all respondents (95.3%) fully 
or partially agreed with this statement (43.5% were in 
full agreement with this statement, while 51.8% were 
in partial agreement). Only 4.7% expressed overall 
disagreement (3.3% partially disagreed and only 1.4% 
completely disagreed).
When asked about the agreement on precision medi-
cine for the development of therapies targeting indi-
vidual patients characteristics (Question 4, see Table 2), 
respondents showed a high level of agreement (96.2%): 
50.5% fully agreed with the statement, and 45.7% par-
tially agreed. Only 3.7% a expressed negative opinions: 
3.2% in partial disagreement, and 0.6% in complete dis-
agreement.
Another question (Question 5, see Table 2) tested the 
level of agreement on precision medicine implying the 
identification of subpopulations with different suscepti-
bility to certain diseases and different response to spe-
cific therapies: 92.6% of respondents agreed (45.5% in 
full agreement, 47.1% in partial agreement), 6.2% par-
tially disagreed and 1.2 % completely disagreed.
With regard to Question 6 (see Table 2), respondents 
were supposed to express their agreement on precision 
medicine and personalized/individualized medicine as 
synonyms. 70.4% of respondents overall agreed (22.1% 
fully agreed, 48.3% partially agreed), while 20.8% of re-
spondents partially disagreed and 8.8% answered they 
completely disagreed.
Question 7 (see Table 2) investigated whether re-
spondents agreed with the idea that precision medicine 
greatly emphasizes the importance of the individual pa-
tient, despite the well known challenging interactions 
between patients and physicians. Most respondents 
(72.9%) agreed (30.2% fully agreed, 42.7% partially 
agreed). A negative opinion was expressed by 27.1% of 
respondents (18.5% partially disagreed, and 8.6% com-
pletely disagreed).
Another question (Question 8, see Table 2) aimed 
at highlighting a critical aspect of precision medicine, 
i.e. the emphasis on disciplines such as molecular biol-
ogy, or immunology – which may represent a potential 
distraction from curing the patients. In this case only 
12.2% fully agreed with this statement, 37.2% partially 
agreed, 32.4% partially disagreed and 18.2% completely 
disagreed.
Another question (Question 9, see Table 2) dealt with 
a particularly sensitive and delicate aspect, namely if 
the paradigm shift imposed by precision medicine may 
decrease the importance of the traditional evidence-
based approach to medicine. 66.5% tended to agree 
with this statement (19.1% fully agreed and 47.4% par-
tially agreed). The remaining 33.5% expressed their dis-
agreement on this statement (23.6% partially disagreed 
and 9.9% completely disagreed).
The idea that precision medicine can be successful 
in treating limited types of diseases with a strong ge-
netic component (Question 10, see Table 2) was agreed 
by the majority of respondents (75.5%), in particular 
29.1% fully agreed, 46.4% partially agreed, 18.2%, par-
tially disagreed, and 6.3% fully disagreed.
The following question (Question 11, see Table 2) 
focused on funding issues. Indeed respondents’ agree-
ment was measured on the issue that precision medi-
cine may potentially cause a funding reallocation, thus 
subtracting resources from sectors more strategically 
important, such as prevention or rehabilitation. The 
analysis revealed that 35.7% of respondents agreed 
(9.5% fully agreed and 26.2 partially agreed) and 64.3% 
overall disagreed (44.5% partially disagreed, and 19.8% 
completely disagreed).
Another question explored the perception of respon-
dents on the outcomes reached so far in certain therapeu-
tic areas e.g., oncology (Question 12, see Table 2) through 
precision medicine: 75.8% of respondents considered the 
results obtained as promising (30.9% very promising and 
44.9% partially promising). Only 0.4% of respondents 
considered the results obtained as not promising at all, 
and 5.6% as not enough to justify the investment. Finally, 
18.2% of survey participants believed they were not suf-
ficiently informed to answer this question. 
The second set of questions tested doubts and con-
cerns of respondents on the healthcare reorganization 
potentially caused by precision medicine, about the 
possible excessive expectations from patients and their 
families, and on the different education and training 
needed by healthcare professionals in relation to preci-
sion medicine (Questions 13, 14 and 15, see Table 2).
Almost all respondents (94.9%) were aware that ad-
vances in precision medicine will require changes in 
terms of hospital organization: 53.6% stated that they 
will probably lead to changes, while 41.3% declared 
changes will definitely occur. Only 4.6% stated that no 
major change of the healthcare organization is expected 
in relation to precision medicine. Answers to this item 
were found to be independent from medical specialties, 
age and geographic area of respondents; possible differ-
ences are thus due to chance. 
40.7% Partially52.6% No 6.7% Yes
Figure 1
Answers to Question 1: “Do you feel informed about precision 
medicine?”
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Interestingly, most respondents (79.4%) believed 
that precision medicine may create excessive expecta-
tions in patients and their families: in particular, 60% 
stated that it will probably create excessive expecta-
tions, 19.4% were absolutely sure it will do, 20.6% did 
not think that precision medicine might create false ex-
pectations in patients and their families (probably not 
17.7%, certainly not 2.9%). Clinical and hospital phar-
macists are more convinced that precision medicine 
might somehow disappoint patients and their families. 
“Probably not” is the most frequent answer given by 
oncologists. 
Almost all respondents (95.4%) are aware that the 
adoption of precision medicine will necessarily require 
changes in education and training of healthcare pro-
fessionals. Only 4.2% believed that changes in train-
ing will probably not be needed. The positive answers 
(“Certainly yes”, “Probably yes”) were found to be in-
dependent from age and gender of respondents, while a 
statistically significant correlation (p = 0.02) was identi-
fied with the medical specialty of respondents, since it 
emerged that clinical/hospital pharmacists and experts 
in infectious diseases more strongly believe in the need 
for healthcare professional’s education specific for pre-
cision medicine. 
Last question (Question 16, see Table 2) was an open 
question to test the comprehensiveness of the survey 
itself. Most respondents (63.5%) answered the survey 
was exhaustive, 2.1 % thought some subjects had not 
been addressed, but did not mentioned which ones. 
28.1% of respondents indicated aspects that should 
have been included, mentioning the economic sustain-
ability of precision medicine, the relationship with gen-
der medicine, the diseases to which precision medicine 
can be applicable, the degrees of its applicability within 
different health care contexts, ethical issues, data bases 
and registries, issues related to patient’s compliance, 
the relationship with pharmaceutical companies’ inter-
ests, and biostatistics. 
Respondents’ answers are summarised in Figure 2 and 
Figure 3.
DISCUSSION
This analysis represents the first systematic attempt 
to look into the actual perception of precision medi-
cine, reporting directly the views and information needs 
Resource allocation in precision medicine
will subtract resources from sectors
more strategically important
Precision medicine can be successful
in treating limited types of
diseases with a strong genetic component
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0%
Completely disagree
Partially disagree
Partially agree
Fully agree
Precision medicine implies health care
decision-making tailored
on patients characteristics
Precision medicine implies
the development of therapies targeting
individual patients characteristics
Precision medicine implies the identification
of subpopulations
with different susceptibility to certain
diseases and different
response to specific therapies
Precision medicine and
personalized/individualized medicine
are synonyms
Precision medicine greatly emphasizes
the importance of the
individual patient. This contrasts with
the typically difficult relationship
between patients and physicians
Precision medicine, shifts the emphasis
on disciplines such as molecular biology, 
or immunology. This may potentially distract
health care professionals from their
core business i.e. curing …
Precision medicine is an alternative
to evidence-based medicine.
Indeed focusing on the individual
patient implies the overcoming
of population-medicine
Figure 2
Summary of answers to question 3-11.
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of Italian health care professionals. Overall the study 
findings show partial knowledge of this topic, which 
may have influenced the willingness of respondents to 
answer the questions, as well as the quality and reliabil-
ity of their answers. This, however, does by no means 
threaten the validity of the study, which still provides a 
reliable overview on this subject.
Are we informed enough?
Feeling well informed about precision medicine 
(roughly 7% of respondents) seems to be strongly asso-
ciated with being aware of the Precision Medicine Ini-
tiative and that the US Government was the institution 
launching this important research project (only 10% of 
correct answers). Nevertheless, in a context of general 
misinformation, it is still reassuring to observe a 15% of 
respondents attributing a coordinating and leading role 
to the World Health Organization. 
Surprisingly, most respondents believed that preci-
sion medicine and personalized/individualized medi-
cine are synonyms (70.4%). It is true that the two terms 
partially overlap and some people still use them inter-
changeably. Our opinion is that precision medicine, 
focusing especially on pharmacogenomics, represents 
the most advanced niche within personalized medicine. 
Of note, these concepts are not new. “What is new is 
that advances in a wide range of fields from genom-
ics to medical imaging to regenerative medicine, along 
with increased computational power and the advent of 
mobile and wireless capability and other technologies, 
are allowing patients to be treated and monitored more 
precisely and effectively and in ways that better meet 
their individual needs”, as Dr. Margaret A. Hamburg, 
former FDA Commissioner, once stated in a speech 
[6]. Her words indicate that precision medicine does 
not “go beyond” – and is still part of – population medi-
cine; whereas one out of three of our respondents sup-
port an opposite view. This strengthens our perception 
on substantial misunderstandings and misinterpreta-
tion of such new concept among respondents.
As previously mentioned, most professionals believe 
that precision medicine is patient centered, and seems 
to conflict with the evidence-based medicine which is 
perceived as the “population (imprecise) medicine”, 
based on the results of large randomized controlled 
trials. However, a patient centered approach does not 
conflict with the evidence based medicine. Indeed, evi-
dence based medicine is conceived to deliver the best 
available care to patients taking into account specifici-
ties such as severity of the disease, risk factors etc. The 
“imprecisions” should rather be identified in the deliv-
ery of services by health care facilities.  
The survey shows heterogeneity among different 
medical specialties, highlighting the need of educa-
tional pathways tailored on specific categories of health 
care professionals. 
The need for a cultural mindshift
Almost all respondents (94%) believed that precision 
medicine requires significant organizational changes 
within the healthcare system. But to what extent and in 
which sectors? Significant challenges exist to precision 
medicine’s broad implementation in health care, includ-
ing infrastructure challenges, slow uptake of genomic 
information into clinical care and research, reimburse-
ment of costly targeted therapies and companion diag-
nostics, and achieving greater patient’s and clinician’s 
engagement and trust [7].
In particular, a cultural change among health care 
professionals is key to the successful implementation of 
precision medicine. A number of American Universities 
have already started to deal with this issue setting up 
specific courses on diagnosis and treatment of diseases 
with a strong genetic component. This is the case of the 
Do you think that precision medicine will
create excessive expectations among
patients and their families
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0%
Do you think that precision medicine will
require changes in the hospital
organization
Do you think that precision medicine will
require a different training of physicians
and pharmacists
Certainly no
Probably no
Probably yes
Certainly yes
Figure 3
Summary of answers to question 13-15.
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Harvard Medical School (https://dbmi.hms.harvard.
edu/), of Duke University (https://medschool.duke.
edu/) and of Stanford University (http://med.stanford.
edu/) for example. Italy has no experience of this kind 
and this is reflected in the answers of our respondents 
(95% of respondents believe that healthcare workforce 
education should be reconsidered and a significant pro-
portion of these answers came from residents of South-
ern Italy and Islands).  
Furthermore, more efforts are needed in the frame-
work of continuing medical education, in line with the 
initiatives implemented at the Genomic Medicine Insti-
tute of Cleveland Clinic (https://my.clevelandclinic.org/
departments/genomics/about) or at the Mayo Clinic’s 
Center for Individualized Medicine (http://mayor-
esearch.mayo.edu/center-for-individualized-medicine/) 
for example, which are organizing courses for both 
healthcare professionals and citizens.
Precision medicine and citizens
Engagement and trust of the public to participate in 
precision medicine research is necessary for the field to 
reach its full potential. Intense research has allowed cut-
ting down the costs of human genome sequencing [8]. 
This constant cost reduction (today, in the US, the cost 
is more or less US$ 1000 – excluding the costs for data 
reading and interpretation) implied a series of conse-
quences: the increasing spread of tests forces doctors to 
be more competent on the issue and at the same time 
citizens are more aware of the opportunities that may 
stem from new treatment options. The personal-genom-
ics screening tests for genetic health risks (including 
one for Alzheimer’s and one for a rare blood disorder) 
recently approved by the FDA, are a clear example of 
the impact of precision medicine on people’s life and 
on the radical change expected in the relationship be-
tween physicians and their patients [9]. The question of 
how positive this change is going to be for patients and 
health care professionals remains still unsolved.
As to the practical impact of precision medicine on 
citizens, the so-called “Angelina Effect” is often men-
tioned. In May 2013, US actress Angelina Jolie re-
vealed, in a New York Times editorial, her decision to 
undergo bilateral mastectomy based on her familiar-
ity for breast cancer, as she was a carrier of a BRCA1 
(Breast Related Cancer Antigens) gene mutation. Ex-
pectedly, the news spread across the world and, in the 
immediately following weeks, an impressive increase in 
the Google search on this matter was registered [10]. 
At the same time, the number of both tests and conse-
quent surgeries rapidly increased. 
A study carried out by a team of the Johns Hopkins 
University showed that 3 out of 4 US citizens knew An-
gelina Jolie’s story and her decision, but only 10% had 
all the necessary information to understand the ratio-
nale for the higher risk run by the actress [11]. Only 
3.4% of the sample had read the editorial on the New 
York Times and the vast majority of people had heard the 
news from television or entertainment magazines. 57% 
of interviewed women declared they would undergo 
surgery and 50% would recommend it to a family mem-
ber under the same Jolie’s circumstances. 
Patients’ expectations tend to become higher, once 
“precision” strategies are able to cure severe and life 
threatening diseases. Our survey respondents seemed 
to be very well aware of it, since most of them (79%) 
believed that precision medicine risks to create exagger-
ated expectations in patients and their families. 
CONCLUSIONS
The barriers to developing precision medicines are 
many. Everyone has a stake in this process; in particu-
lar health care professionals, using genomic and other 
information in routine health care delivery will be 
crucial to integrating precision medicine into health 
systems. 
Despite some misconceptions about precision medi-
cine, a genuine interest and familiarity with its basic 
principles seem to emerge among the health care pro-
fessionals. Based on that, it is reasonable to expect that 
further investments in educating the health care work-
force will lead to rapid positive changes over the next 
few years. However, challenges to the clinical adoption 
of precision medicine should be uncovered and poten-
tial solutions should be outlined.
Availability of data and materials
Datasets will be made available by authors upon re-
quest. 
This article is based on an online short report pre-
viously published in Italian on the Forward project 
website available at: http://forward.recentiprogressi.it/
numero-1/i-risultati-della-survey/.
Conflict of interest statement
The authors have declared no conflicts of interest.
Funding
No author received funding for this manuscript.
This survey was conducted within the Forward proj-
ect, an independent public-private partnership uncon-
ditionally funded by the Italian publisher “Il Pensiero 
Scientifico”, the Epidemiology Department of the Re-
gional Government of Lazio and by private companies 
in the health care industry. This partnership aims to dis-
seminate independent information on medicines and 
health policy and operates under specific rules available 
at: http://forward.recentiprogressi.it/policy/
Author contributions 
AA and LDF made substantial contributions to con-
ception, design of the survey and data collection, while 
FT and GT drafted the article. All authors contributed 
to the analysis and interpretation of data and gave final 
approval of the version to be submitted and of any re-
vised version.
Acknowledgments
Authors thank the Forward Working Group for 
contributing to the design of the survey. The Forward 
Working Group is composed of representatives from 
the Department of Epidemiology of the Regional 
Health Service of the Lazio Region, from the pub-
lisher “Il Pensiero Scientifico Editore” as well as from 
InformatIon needs on precIsIon medIcIne
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
323
the following pharmaceutical companies: Abbvie, Am-
gen, Daiichi-Sankyo, Fondazione MSD, Pfizer, Gilead, 
GSK, Novartis.
Authors also thank Luciano De Fiore, Maria Nardo-
ianni e Laura Tonon (Think2it srl) who coordinated the 
activities related to the distribution and collection of 
the questionnaires.
The views expressed in this article are the personal 
views of the survey respondents and the authors and 
may not be understood or quoted as being made on 
behalf of or reflecting the position of the Italian Medi-
cines Agency, or the Department of Epidemiology of 
the Regional Government of Lazio.
Received on 25 May 2018.
Accepted on 4 September 2018.
REFERENCES
1. Personalized medicine at FDA. 2016 Progress Report. 
Available from: www.personalizedmedicinecoalition.org/
Userfiles/PMC-Corporate/file/PM-at-FDA.pdf .
2. Priorities for Personalized Medicine.  Report of the Presi-
dent’s Council of Advisors on Science and Technology. 
Washington DC; September 2008. 
3. Trusheim MR,  Berndt ER. Economic challenges and 
possible policy actions to advance stratified medicine. 
Person Med. 2012;9: 413-27.
4. The German Federal Ministry of Education and Re-
search (BMBF) Action Plan for Individualized Medicine 
“Individualized Medicine. A New Way in Research and 
Healthcare”. Available from: www.bmbf.de. 
5. Vicini P et al. Precision medicine in the age of Big Data. 
The present and future role of large scale unbiased se-
quencing in drug discovery and development. Clin Phar-
macol Ther. 2016;99(2):198-207.
6. Hamburg MA. Paving the way for personalized medicine. 
FDA’s role in the new era of medical product develop-
ment (2013). Available from: www.fda.gov/downloads/
scienceresearch/specialtopics/personalizedmedicine/
ucm372421.pdf.
7. Realizing the Full Potential of Precision Medicine in 
Health and Health Care JAMA. 2016;316(16):1659-60.
8. National Institute of Health (NIH). The Cost of Se-
quencing a Human Genome. Available from:  www.ge-
nome.gov/sequencingcosts.
9. Huber P, Howard P. Personalized medicine is here. The 
Wall Street Journal, 30 April 2017. Available from: www.wsj.
com/articles/personalized-medicine-is-here-1493584199.
10. The “Angelina Effect” in Four Charts. Huffington Post 
US ed. Available from: www.huffingtonpost.com/brian-
reid/angelina-jolie-double-mastectomy_b_3354589.html.
11. Borzekowski DLG, et al. The Angelina effect. The im-
mediate reach, grasp, and impact of going public. Genet 
Med. 2014;16:516-21.
